According to the website of the Ministry of Commerce, on March 21, Minister of Commerce Wang Wentao met with Dai Wenrui, Chairman and CEO of Eli Lilly Pharmaceuticals. Both sides exchanged views on topics such as China US economic and trade relations, and the development of Eli Lilly Pharmaceuticals in China.
Wang Wentao stated that health is an important symbol of a better life for the people, and China insists on putting the people at the center and solidly promoting the construction of a healthy China. China is the world's second-largest pharmaceutical consumer market, which will create vast space for multinational pharmaceutical companies, including Eli Lilly. Lilly Pharmaceutical has been deeply rooted in China for many years and hopes to continue investing in China, providing more high-quality pharmaceutical products and services, and contributing to the health and well-being of the people and the development of the pharmaceutical industry. China adheres to promoting high-quality development through high-level opening up to the outside world, continuously creating a market-oriented, legal, and internationalized first-class business environment, and providing good service guarantees for foreign-funded enterprises.
Dai Wenrui introduced the global business development of Eli Lilly Pharmaceuticals, stating that they attach great importance to the Chinese market and will continue to increase investment and research and development cooperation in China to provide better products and services for the Chinese market.